Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine
Latest Information Update: 23 Aug 2023
At a glance
- Drugs AD 036 (Primary) ; Atomoxetine
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Apnimed
Most Recent Events
- 30 Mar 2021 Status changed from active, no longer recruiting to completed.
- 21 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2020 Status changed from not yet recruiting to recruiting.